Adient ADNT Gain (Loss) On Sale Of Equity Method Investment, And Other Than Temporary Impairment
Gain (Loss) On Sale Of Equity Method Investment, And Other Than Temporary Impairment at other companies
Other financials
Where this comes from
Reported directly by Adient in its filing.
Tagged under the XBRL concept adnt:GainLossOnSaleOfEquityMethodInvestmentAndOtherThanTemporaryImpairment.
The official record: Adient’s 10-Q, filed May 6, 2026, on SEC EDGAR. View the filing →
Ask your AI about Adient's gain (loss) on sale of equity method investment, and other than temporary impairment.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Adient's gain (loss) on sale of equity method investment, and other than temporary impairment?
- Adient (ADNT) reported gain (loss) on sale of equity method investment, and other than temporary impairment of $0 in Q1 2026.
- What is the long-term trend for Adient's gain (loss) on sale of equity method investment, and other than temporary impairment?
- Over 2 years (2021 to 2023), Adient's gain (loss) on sale of equity method investment, and other than temporary impairment has grown at a -92.9% compound annual growth rate (CAGR), from $1.19B to -$6M.
- What does gain (loss) on sale of equity method investment, and other than temporary impairment mean?
- Captures the realized gains or losses resulting from the divestiture of interests in equity-method affiliates, alongside any recognized impairment charges on these investments. This reflects the performance and strategic value of the company's unconsolidated joint ventures and partnerships.